Suppr超能文献

抢救治疗:环孢素还是英夫利昔单抗?

Rescue therapy: ciclosporin or infliximab?

机构信息

Inflammatory Bowel Disease Unit, Dipartimento di Scienze Mediche e Chirurgiche-DIMEC, Ospedale Sant'Orsola-Malpighi, University of Bologna, via Massarenti 9, Bologna 40138, Italy.

出版信息

Expert Rev Clin Immunol. 2013 Jun;9(6):503-5. doi: 10.1586/eci.13.34.

Abstract

Severe active refractory ulcerative colitis is a potentially life-threatening disease. The introduction of intensive steroid treatment and early surgery has reduced mortality in recent years. Ciclosporin and infliximab are effective rescue therapies in steroid refractory colitis. A head-to-head study proposed by Laharie et al. failed to demonstrate the superiority of ciclosporin but confirmed the efficacy and safety of infliximab to control active disease and to maintain remission.

摘要

严重活动期难治性溃疡性结肠炎是一种潜在的危及生命的疾病。近年来,强化类固醇治疗和早期手术的引入降低了死亡率。环孢素和英夫利昔单抗是类固醇难治性结肠炎的有效挽救治疗方法。Laharie 等人提出的一项头对头研究未能证明环孢素的优越性,但证实了英夫利昔单抗控制活动性疾病和维持缓解的疗效和安全性。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验